About this NAD+ research digest
A research briefing that maps the peer-reviewed NAD+ literature — what it is, what it is not, and how it is sourced.
What Clinic NAD+ is
Clinic NAD+ is a research briefing on NAD+ (nicotinamide adenine dinucleotide) and its precursors — a sourced reading of the peer-reviewed literature, organized as a map of the NAD+ ecosystem: the core coenzyme, its orbiting precursors, the pathways that build it and the enzymes that spend it. It runs no exam room and keeps no clinical staff; no one here diagnoses, treats, or writes a prescription. Nothing is made, sold, or supplied from these pages — no NAD+, no NMN, no NR, no infusions, nothing.
What the name means
The word "clinic" in the name is a register, not a service. It signals the measured, instrument-panel tone of the briefing — a place where the NAD+ literature is read carefully and logged to source — not a healthcare facility, an IV-drip bar, or a storefront. It holds no clinical position toward any reader. It does not consult, prescribe, infuse, or book appointments. If you are looking to buy a product or undergo a therapy, this is not that site; if you want to understand what the published studies on NAD+ actually measured, that is exactly what it does.
How we source and frame
Every quantitative claim here — every dose, percentage, duration and effect size — is tied to a numbered citation drawn from the published literature: randomized human trials, mechanism reviews, human-tissue studies and preclinical work, listed on the study references and citations page with DOIs and PubMed links. Three lines are kept bright. First, the supplement-versus-precursor distinction: NAD+ itself is poorly absorbed orally, so an oral-NMN or oral-NR study is never described as "taking NAD+". Second, the evidence ladder: confirmed human findings, preclinical findings and honest gaps are labeled as such, never blended. Third, regulatory accuracy: NAD+ and its precursors are dietary supplements, not approved drugs, and IV NAD+ is an unapproved compounded therapy — the briefing reports that status plainly and makes no therapeutic claims.